GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Interest Expense (Positive)

Bright Minds Biosciences (XCNQ:DRUG) Interest Expense (Positive)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.


Bright Minds Biosciences Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Executives
Ryan Cheung Senior Officer
Nils Bottler Director
Jeremy Fryzuk Director
Alan Kozikowski 10% Security Holder, Director, Senior Officer
Ian Mcdonald Director